Both Novo Nordisk’s and competitor Eli Lilly’s injectable GLP-1 drugs, Wegovy and Zepbound, have helped transform obesity treatment around the world, and for the 100 million people in the U.S. impacted by the disease, according to NPR. But Eli Lilly’s oral drug orforglipron is still awaiting approval, with a decision expected by spring.